Biocare Medical and Bethyl Laboratories Announce Strategic Partnership for Antibody Development

Biocare Medical announces a collaborative partnership with Bethyl Laboratories to develop targeted antibodies for cancer research and oncology diagnostics.

Bethyl Laboratories has 45 years of experience in antibody development and has been dedicated to supporting scientific discovery to advanced laboratories around the world. This strategic partnership provides strong synergy for Biocare Medical to accelerate Bethyl’s research antibodies into the clinical market space.

“Bethyl Laboratories is committed to improving lives by supporting scientific discovery and to facilitate clinical diagnostics by providing the highest quality antibody reagents,” said John M. Carwile, MD, Chief Executive Officer of Bethyl. “We are very excited to partner with the forward-looking, innovative and quality-focused team at Biocare.”

Bethyl will also partner with Biocare Medical to develop novel solutions in automated IHC workflow that will expand the options in IHC platforms available to pharmaceutical and biotech research institutions.

Biocare is delighted to offer Bethyl Laboratories premier access to the newly launched VALENT automated IHC platform. The partnership will create unparalleled possibilities for customers in early-stage research, companion diagnostics development, and those looking to accelerate their diagnostic workflow.

“This new relationship is a natural complement to our instrument platforms and reagent portfolio,” said Luis de Luzuriaga, CEO, Biocare Medical. “We believe that the close alliance between our two companies will enable us to develop a continuous cadence of novel, unique offerings to both the clinical and life science research markets, significantly expanding our life science research reagent portfolio with high-impact products.”

Biocare Medical is excited to announce this strategic collaboration with Bethyl Laboratories. Both companies have established themselves with strong core values around respect, excellence, speed, and service combined with innovation and a relentless desire to improve both cancer research and diagnostics.